Advances in surgical treatment for valvular heart disease: a narrative review of 2025 studies Authors: Jiaqi Wu, Ming Chen, Chen Jiang, Xingyu Qian, Keqing Yu, Yidan Zheng, Pengning Fan, Yuqi Liu, Jiu Pu, Lin Fan, Zhe Chen, Haoyang Zhai, Zhengfeng Fan, Jian Sun, Teng Zeng, Zihao Zhou, Li Xu, Fei Li Published: 2026 ABSTRACT Background and ObjectiveThe field of surgical treatment for valvular heart disease (VHD) has progressed rapidly in 2025. This review aims to summarize the year’s key research, focusing on comparisons of mainstream techniques for aortic, mitral, and tricuspid valve diseases, innovations in repair techniques, and advances in emerging technologies, to provide evidence-based support for individualized clinical decision-making.MethodsA structured search of PubMed database was performed to identify randomized controlled trials (RCTs), registry studies, and meta-analyses published in 2025, and the evidence was synthesized narratively.Key Content and FindingsIn the aortic valve arena, long-term follow-up from the PARTNER 3 and Evolut Low Risk trials confirmed the non-inferiority of transcatheter aortic valve replacement (TAVR) in low-risk patients. However, real-world data suggested higher long-term risks with TAVR in patients with bicuspid aortic valves (BAV) and younger patients, whereas women demonstrated greater benefit. The indication for early intervention in asymptomatic severe aortic stenosis (AS) was reinforced. Aortic valve repair and the Ross procedure accumulated more robust evidence for long-term survival and quality of life in younger patients. In the mitral valve domain, the MITRACURE study highlighted gaps between real-world practice and guidelines, including delayed referral and suboptimal repair rates for mitral regurgitation (MR). The advantages of repair for degenerative disease were further solidified, though techniques for posterior leaflet prolapse and management strategies for atrial functional regurgitation (AFMR) require optimization. Transcatheter edge-to-edge repair (TEER) was increasingly used in high-risk patients but yielded inferior long-term outcomes compared to surgery, and surgical rescue after failed TEER carried high risk. For the tricuspid valve, comparative effectiveness of transcatheter vs. surgical repair and the timing of intervention emerged as key research foci. Emerging technologies such as polymer valves, partial heart transplantation, and artificial intelligence (AI)-assisted analysis demonstrated preliminary potential.ConclusionsThe 2025 evidence reinforces a paradigm shift from risk-score-based decision-making toward individualized valve care. Transcatheter techniques have expanded their indications, but surgery remains irreplaceable in young, low-risk, and BAV patients, as well as in degenerative MR. Real-world gaps in guideline adherence, delayed referral, and suboptimal repair rates require urgent attention. Emerging technologies show early promise, although their long term durability and clinical value await further validation. Introduction Valvular heart disease (VHD) is a leading cause of heart failure and cardiovascular mortality worldwide. With the acceleration of population aging, the prevalence of degenerative valve disease, particularly aortic stenosis (AS), continues to rise, placing an increasing burden on healthcare systems. Over the past two decades, the rapid evolution of transcatheter aortic valve replacement (TAVR) has profoundly impacted traditional surgical aortic valve replacement (SAVR). Its indications have expanded from inoperable or high-risk patients to those at intermediate and low surgical risk (1). This paradigm shift has reshaped the treatment landscape for AS and prompted renewed scrutiny of the role of surgery. In particular, how to balance the less invasive nature of TAVR against the long-term durability of SAVR in low-risk patients, and which patient groups should still be prioritized for surgery, have become central questions in contemporary valve practice (2-6). However, while expanding therapeutic boundaries, these innovations also introduce complex clinical dilemmas. Optimizing repair strategies for mitral regurgitation (MR) of different etiologies, defining the optimal timing for tricuspid valve intervention, and addressing the discrepancies between real-world clinical practice and randomized controlled trial (RCT) results are critical issues that need urgent clarification (5-7). Furthermore, the emergence of novel technologies such as polymer valves, partial heart transplantation, and artificial intelligence (AI)-assisted decision-making is creating new possibilities for surgical treatment, although their clinical value still requires validation through robust evidence (8-10). Based on this background, this article reviews key clinical trials and real-world studies published in 2025 from the perspective of surgical treatment for VHD. It focuses on comparisons of mainstream surgical techniques, innovations in repair, and progress in emerging technologies for aortic, mitral, and tricuspid valve diseases, aiming to provide clinicians with an evidence-based reference for decision-making. We present this article in accordance with the Narrative Review reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0842/rc). Methods We conducted a literature search in the PubMed database for studies published between January 1 and December 31, 2025. The search strategy combined MeSH terms and free text related to aortic, mitral, and tricuspid valve diseases, surgical and transcatheter interventions, and relevant study types (RCTs, registries, meta-analyses). The detailed search strategy is summarized in Table 1. Key RCTs discussed in this review are summarized in Table 2. Table 1The search strategy summaryItemsSpecificationDate of searchFebruary 22, 2026Databases searchedPubMedSearch terms usedMeSH (Medical Subject Headings) terms and free text were combined. The main search strategy included: (“aortic valve stenosis”[MeSH] OR “aortic valve regurgitation”[MeSH] OR “mitral regurgitation”[MeSH] OR “tricuspid regurgitation”[MeSH]) AND (“surgical aortic valve replacement” OR “SAVR” OR “aortic valve repair” OR “mitral valve repair” OR “mitral valve replacement” OR “Ross procedure”[MeSH] OR “polymer valve”) AND (“randomized controlled trial”[PT] OR “clinical trial” OR “registry” OR “meta-analysis” OR “long-term” OR “prehabilitation”)TimeframeRCTs, registry studies, and meta-analyses published between January 01, 2025 and December 31, 2025Inclusion and exclusion criteriaInclusion criteria: (I) study population comprised patients with aortic, mitral, or tricuspid valve disease; (II) intervention involved surgical procedures; (III) reported clinical outcomes (e.g., mortality, stroke, rehospitalization, reintervention); (IV) study type: RCTs, large prospective/retrospective cohort studies, registry studies, or high-quality meta-analysesExclusion criteria: (I) case reports, commentaries, reviews; (II) studies primarily focusing on basic science or animal experiments; (III) conference abstracts or unpublished literatureSelection processTwo reviewers independently screened titles and abstracts, followed by full-text assessment of potentially eligible studies. Disagreements were resolved through discussionRCT, randomized controlled trial. The search strategy summary RCT, randomized controlled trial. Table 2Summary of key RCTs in 2025TrialPopulationIntervention vs. controlKey findings (follow-up)PARTNER 3 (7-year)Low-risk ASTAVR vs. SAVRNo significant difference in composite of death, stroke, or rehospitalization (34.6% vs. 37.2%)Evolut Low Risk (5-year)Low-risk ASSelf-expanding TAVR vs. SAVRComparable all-cause mortality or disabling stroke (15.5% vs. 16.4%)NOTION-2 (3-year)Low-risk AS (age 60–75 years, including BAV)TAVR vs. SAVROverall HR 1.3 (non-significant); BAV subgroup trend favoring SAVR (HR 2.9)RHEIA (1-year)Women with severe ASTAVR vs. SAVRTAVR superior for composite endpoint (8.9% vs. 15.6%, P=0.03)TCW (1-year)Age ≥70 years with AS and complex CADPCI + TAVR vs. CABG + SAVRLower composite endpoint with PCI + TAVR (4% vs. 23%, P<0.001)AS, aortic stenosis; BAV, bicuspid aortic valve; CABG, coronary artery bypass grafting; CAD, coronary artery disease; HR, hazard ratio; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement. Summary of key RCTs in 2025 AS, aortic stenosis; BAV, bicuspid aortic valve; CABG, coronary artery bypass grafting; CAD, coronary artery disease; HR, hazard ratio; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement. Aortic valve disease Timing of intervention in asymptomatic patients Historically, guidelines recommended clinical surveillance for patients with asymptomatic severe AS and preserved left ventricular ejection fraction (LVEF) (11). Généreux et al. conducted a study-level meta-analysis of four RCTs (12), including 1,427 patients with asymptomatic severe AS and preserved LVEF, comparing early aortic valve replacement (AVR) (surgical or transcatheter) with clinical surveillance. At a median follow-up of 4.1 years, early intervention was associated with significantly reduced risks of cardiovascular/heart failure rehospitalization [14.6% vs. 31.9%; hazard ratio (HR) 0.40] and stroke (4.5% vs. 7.2%; HR 0.62). However, no statistically significant differences were observed for all-cause or cardiovascular mortality, with considerable heterogeneity among studies. This study provided key evidence supporting the 2025 European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) guideline recommendation (class IIa, level A) for considering early intervention in asymptomatic low-surgical-risk patients (13). The evolution of evidence and real-world considerations for TAVR vs. SAVR As TAVR expanded from initially high-risk patients to intermediate- and low-risk patients, a series of high-quality studies provided evidence for decision-making across different risk strata. Early comparisons focused on high-risk patients. The 5-year results from the Placement of Aortic Transcatheter Valves (PARTNER) 1 high-risk cohort [mean Society of Thoracic Surgeons (STS) risk score 11.7%] showed similar all-cause mortality for TAVR and SAVR (67.8% vs. 62.4%, HR 1.04) (14). Concurrently, the CoreValve High Risk trial confirmed comparable 5-year mortality between self-expanding TAVR and SAVR (55.3% vs. 55.4%) (15). Subsequently, research extended to intermediate-risk patients: the PARTNER 2 and Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trials demonstrated non-inferiority of TAVR (balloon-expandable and self-expanding valves) compared to SAVR for primary endpoints at 2 and 5 years, respectively (16,17). In 2025, long-term data from two landmark low-risk trials were published. The 7-year results of the PARTNER 3 trial showed no significant difference in the primary composite endpoint (all-cause death, stroke, or rehospitalization related to the procedure, valve, or heart failure) between TAVR and SAVR (34.6% vs. 37.2%, difference −2.6 percentage points) (2). Similarly, the 5-year results from the Evolut Low Risk trial demonstrated comparable rates of all-cause mortality or disabling stroke (15.5% vs. 16.4%, P=0.47) (4). These RCT results collectively confirm the long-term effectiveness of TAVR across high, intermediate, and low-risk patients, supporting the expansion of its indications in clinical decision-making. Real-world data, however, tell a more nuanced story. A cross-sectional study using the STS Adult Cardiac Surgery Database (STS ACSD) (Mori et al.) simulated low-risk trial populations and found that 30-day mortality for SAVR in routine clinical practice was similar to trial results, while stroke rates (1.25%) were significantly lower than those in the SAVR arms of both low-risk trials (2.4% and 3.4%), affirming the reliable short-term safety of surgery in the real world (18). Conversely, two real-world analyses using the US Medicare database offered differing perspectives on long-term TAVR outcomes. Mehaffey et al., analyzing low-risk patients, found that despite perioperative advantages in death and stroke for TAVR, it was associated with higher risks of late stroke (HR 1.65), reintervention (HR 1.88), and all-cause mortality (HR 1.54) at 3 years compared to SAVR (19). Extending follow-up to 5 years, Wolfe et al. reported that in low- and intermediate-risk patients, SAVR was associated with a lower risk of the composite endpoint of death, stroke, or reintervention, with low-risk patients having a 28% lower risk of stroke readmission compared to TAVR (HR 0.72) (7). These findings suggest that the non-inferiority conclusions from RCTs need careful consideration and adaptation to individual patient characteristics when translated into clinical practice. Treatment strategies for special populations Younger patients and those with bicuspid aortic valves (BAV) are a current focus. Guidelines preferentially recommend SAVR for patients aged ≤65 years (13). Alabbadi et al., using a California database, analyzed young patients undergoing isolated valve replacement for AS between 2016 and 2021. Despite a marked increase in TAVR utilization (from 7.2% to 45.7%), TAVR was associated with significantly higher 5-year all-cause mortality (HR 2.5), along with increased risks of stroke, reintervention, and rehospitalization (5). The authors suggested these data may support current guideline recommendations favoring SAVR in younger patients with severe AS. BAV is the most common congenital cardiac anomaly, with a prevalence of approximately 0.5–0.77% in the general population (20). The anatomical complexity of BAV has important implications for treatment strategy selection. The NOTION-2 trial was the first RCT to include patients with BAV, comparing TAVR and SAVR in low-risk patients aged 60–75 years over 3 years. In the overall population, the incidence of the primary composite endpoint was 16.1% in the TAVR group vs. 12.6% in the SAVR group [HR 1.3, 95% confidence interval (CI): 0.8–2.2] (3). However, in the BAV subgroup, TAVR showed a trend towards higher event rates (20.4% vs. 7.8%, HR 2.9), whereas outcomes were comparable in the tricuspid aortic valve subgroup. A further analysis of this study demonstrated that among low-risk BAV patients aged ≤70 years, TAVR was associated with a significantly higher risk of adverse events at 1 year compared to SAVR (absolute risk difference 13.8%) (21). A Medicare database analysis by Mehaffey et al. of 11,289 BAV patients similarly found that despite lower procedural mortality with TAVR [odds ratio (OR) 0.40], it was associated with higher 5-year risks of stroke (HR 1.35) and all-cause mortality (HR 1.49) compared to SAVR (6). Additionally, a study by Wedin et al. suggested that patients with BAV undergoing SAVR have a higher risk of conduction disturbances, with higher rates of new-onset left bundle branch block (9.7% vs. 5.7%) and third-degree atrioventricular block (6.5% vs. 2.5%) compared to patients with tricuspid aortic valves, and new-onset left bundle branch block was associated with increased long-term mortality (HR 1.60) (22). These findings suggest that SAVR should remain the preferred strategy in patients with BAV, with individualized risk assessment based on BAV subtype. Sex differences also influence outcomes. The Randomized research in women all comers with Aortic stenosis (RHEIA) trial, the first RCT specifically designed for women with AS, demonstrated that TAVR was superior to SAVR for the 1-year composite endpoint (8.9% vs. 15.6%, P=0.03) (23). Subgroup analysis of the DEDICATE-DZHK6 trial showed that women undergoing TAVR had significantly lower 1-year death or stroke rates compared to SAVR (5.2% vs. 11.5%, HR 0.46), with the stroke rate after SAVR being more than double that after TAVR (6.2% vs. 2.6%) (24). Approximately half of patients undergoing AVR have significant concomitant coronary artery disease (CAD) (25). Recent evidence has accumulated on revascularization strategies for these patients. The TCW trial, the first RCT comparing percutaneous coronary intervention (PCI) plus TAVR vs. coronary artery bypass grafting (CABG) plus SAVR in patients aged ≥70 years with complex CAD, showed that the PCI + TAVR group had a significantly lower 1-year composite endpoint rate (4% vs. 23%, P<0.001), driven mainly by differences in all-cause mortality (0% vs. 10%) and life-threatening bleeding (2% vs. 12%) (26). However, a Medicare-based analysis by Jagadeesan et al. including 37,822 patients found that over 5 years, the PCI + TAVR group had a higher risk of the composite endpoint of death, stroke, myocardial infarction (MI), or valve reintervention compared to the CABG + SAVR group (HR 1.29) (27), highlighting the critical balance between short-term safety and long-term durability. Aortic valve repair and the Ross procedure Aortic valve repair has become an important strategy for treating aortic regurgitation (AR) (28). While bioprosthetic valve replacement is widely used, it carries concerns about limited durability and increasing reintervention risk over time; mechanical valves require lifelong anticoagulation with associated bleeding and thromboembolic risks. In this context, aortic valve repair, which preserves native leaflet tissue, restores physiological hemodynamics, and avoids prosthesis-related complications, has gained increasing attention in suitable patients. A study by Zito et al., based on the Heart Valve Society database, confirmed that 10-year survival after various repair techniques is comparable to the general population, with valve-sparing root replacement having the lowest reintervention rate (8.5%) (29). The use of expansible annuloplasty rings can further reduce reoperation rates (30). In patients with BAV, the David procedure (reimplantation technique) demonstrated a 10-year survival of 93.4% and freedom from reintervention of 89.2% (31). For non-repairable aortic valve lesions, the Ross procedure (pulmonary autograft replacement) is gaining traction in younger patients (32). One study including 149 children and young adults reported a 15-year freedom from autograft reoperation rate of 95% and 0% hospital mortality (33). Another study with 25-year follow-up in young adults showed survival of 70%, 10-year freedom from reintervention of 89%, and better postoperative mental health scores compared to the general population (34). Management of prosthetic valve failure With the increasing use of bioprosthetic valves, reintervention for structural valve deterioration poses a new clinical challenge. A meta-analysis by Dimitriadis et al. showed that valve-in-valve TAVR (ViV-TAVR) is associated with lower 30-day and 1-year mortality compared to redo-SAVR, but carries higher risks of postoperative transvalvular gradients and patient-prosthesis mismatch (35). A real-world analysis by Awtry et al. further suggested that despite higher perioperative risk, redo-SAVR offers better 5-year survival than ViV-TAVR, a benefit particularly evident in patients with longer life expectancy (36). The ongoing Repeat Intervention for Deteriorated Surgical Bioprosthetic Aortic Valves (REPEAT) RCT aims to compare the 5-year composite endpoint between these two strategies in low-to-intermediate risk patients, potentially providing higher-level evidence for clinical decision-making (37). Mitral valve disease Clinical challenges in mitral valve surgery (MVS): delayed referral and suboptimal repair rates MITRACURE, a large multicenter registry involving 40 centers in France and Canada, enrolled 3,522 patients undergoing MVS in 2019, providing a systematic picture of the clinical characteristics, management patterns, and in-hospital outcomes of patients with MR in the real world (38). The study revealed that patients were often referred late in the disease process: 43% were in New York Heart Association (NYHA) class III/IV, 35% had reduced LVEF, and 22% had pulmonary hypertension. Only 3% met criteria for early intervention (class I/IIa indications). Regarding treatment, while the repair rate for myxomatous disease reached 80%, the overall repair rate was only 62%. In-hospital mortality was 4.5% overall (1.8% for isolated surgery, 3.1% for combined procedures). Furthermore, diagnostic standardization was lacking, with only 43% of patients receiving quantitative MR assessment. These data reflect the clinical reality of an unselected patient population and highlight gaps in guideline adherence and multidisciplinary collaboration, indicating a need for further optimization of MR management strategies. Degenerative MR In the surgical treatment of degenerative MR (DMR), mitral valve repair (MVr) offers significantly better long-term survival, and lower risks of heart failure rehospitalization and stroke compared to mitral valve replacement (MVR) (39). A study by Del Forno et al. from a high-volume center with long-term follow-up reported a 10-year survival of 89.7% and a reoperation rate of only 3.4% after MVr, with the advantage being particularly pronounced in DMR patients (40). Regarding posterior leaflet prolapse, the optimal technique between traditional resection and neochord implantation remains debated. Resection has been associated with lower rates of moderate or greater MR recurrence at 5 years (7.0% vs. 16.1%) (41), though current evidence is largely derived from observational studies and lacks long-term head-to-head randomized data. Regarding recurrence following repair for advanced degenerative disease, Chen et al. identified LV-annulus mismatch, defined as a left ventricular end-systolic diameter to prosthetic orifice area ratio (LVESD/POA) exceeding 12.25 mm/cm2, as an independent predictor of recurrent MR and adverse remodeling after repair for advanced degenerative disease, emphasizing preoperative proportionality assessment (42). Atrial functional MR (AFMR) AFMR is recognized as a distinct etiological entity, with surgical management and clinical prognosis differing significantly from degenerative MR and ventricular functional MR (VFMR) (43). Del Forno et al. showed excellent outcomes for degenerative disease (40), whereas long-term survival after AFMR surgery is primarily constrained by the progression of atrial fibrillation (AF) and heart failure. Chen et al. suggested that, compared to VFMR, AFMR patients have better-preserved LV function and may experience superior early postoperative outcomes (44). Rheumatic mitral valve disease Surgical strategies for rheumatic mitral valve disease require individualization. Jia et al. found that while repair was associated with lower long-term mortality and stroke rates compared to replacement, with comparable reoperation rates, prior percutaneous balloon commissurotomy significantly increased the risk of reoperation after repair (45). For patients over 60 years, Zhang et al. reported comparable mid-to-long-term survival between repair and bioprosthetic replacement, but repair was associated with less perioperative trauma (46). Minimally invasive and robotic surgery Minimally invasive and robotic techniques have matured. Chikwe et al., analyzing 1,410 procedures, demonstrated a robotic mitral repair rate of 99.5%. In experienced centers, subsequent surgeons could adopt the technique with better-than-predicted outcomes from the outset (47). Sawma et al., in a comparative study of patients aged ≥65 years, confirmed that robotic surgery offers advantages over sternotomy in terms of transfusion rates, postoperative AF, and hospital stay, with comparable long-term survival and reintervention rates (48). With iterative upgrades in robotic systems and accumulating operator experience, the application of robotic technology in treating degenerative MR is expected to expand, although its long-term efficacy remains to be established in broader and less selected patient populations. TEER vs. surgery Transcatheter edge-to-edge repair (TEER) is widely used in high-risk patients with MR. Chikwe et al. reported that in patients with degenerative MR, 3-year survival after TEER was significantly lower than after surgical repair (65.9% vs. 85.7%), with higher rates of heart failure readmission and reintervention (49). Danesh et al. similarly found that in patients aged ≥80 years, despite shorter hospital stays with TEER, the surgery group had superior 5-year survival and lower MR recurrence rates (50). Surgical management following failed TEER presents a substantial challenge. A meta-analysis reported a 30-day mortality of 12.2% for patients undergoing surgery after failed TEER (51). Marin-Cuartas et al. using the CUTTING-EDGE registry, further confirmed that 92.5% of these patients required valve replacement (MVR), and the replacement group had significantly higher 1-year mortality compared to the repair group (33.3% vs. 10.5%) (52). These studies indicate that the long-term benefits of TEER in young, low-risk patients remain unclear, while surgical repair maintains an irreplaceable advantage. Tricuspid valve disease Treatment strategies for tricuspid valve disease are undergoing a significant shift. Hua et al., studying patients undergoing redo cardiac surgery, found that tricuspid valve repair offered significant advantages over replacement: shorter hospital stay, less anticoagulation-related bleeding, and higher 5-year survival (82.8% vs. 75.6%) (53). For surgically high-risk patients, a network meta-analysis by Saito et al. demonstrated that transcatheter intervention significantly reduced long-term mortality compared to medical therapy and had lower perioperative complications than surgery (54). Shimoda et al., using Medicare data, confirmed that tricuspid TEER (T-TEER) and surgical repair had comparable 2-year mortality, but T-TEER was associated with lower in-hospital mortality and pacemaker implantation rates (55). A study by Gwak et al. in patients with moderate-to-severe tricuspid regurgitation (TR) found that surgery in low-to-intermediate risk patients was associated with a significantly lower risk of death compared to medical management (HR 0.38), underscoring the critical importance of timely intervention (56). Emerging technologies The landscape of emerging technologies is diverse. Polymer valves represent a significant breakthrough in materials science, aiming to combine the durability of mechanical valves with the favorable hemodynamics of bioprosthetic valves, while avoiding lifelong anticoagulation and structural deterioration. One-year results for the Tria mitral valve in 67 patients with predominantly rheumatic disease showed stable hemodynamics (mean gradient 4.6 mmHg) and no structural valve deterioration or valve-related deaths, providing initial confirmation of its safety and hemodynamic performance (9). However, these early findings require confirmation in larger cohorts with extended follow-up before widespread adoption can be recommended. Partial heart transplantation offers living valve tissue with growth potential for infants and children with irreparable congenital valve lesions. An analysis of the first 19 recipients by Overbey et al. demonstrated that the transplanted valve annulus (from 7 to 14 mm) and leaflet length (from 0.5 to 1 mm) grew with the child, with good valve function. The postoperative immunosuppression regimen primarily used tacrolimus monotherapy, with no significant complications observed (8). This technology overcomes the limitations of traditional bioprostheses (lack of growth) and mechanical valves (lifelong anticoagulation), opening a new therapeutic pathway for children with complex congenital heart disease (CHD). Progress has also been made in AI-assisted surgical analysis tools. Lan et al. developed TMVP-SurgVideo, the first large-scale annotated video dataset specifically for thoracoscopic mitral valvuloplasty (TMVP). They also proposed a Transformer-based multi-task analysis framework, SurgFormer, capable of simultaneously recognizing and predicting surgical phases and instrument usage. This provides data support and an algorithmic foundation for developing intelligent assistance systems in minimally invasive valve surgery (10). Although these explorations are still in their early stages, they demonstrate potential value for advancing surgical standardization and homogeneity. Limitations This review has several limitations. First, the literature search was confined to the PubMed database, potentially omitting relevant studies indexed elsewhere. Second, as a narrative review, it does not employ the rigorous methodological framework of a systematic review or meta-analysis, and the synthesis of conclusions may be subject to selection bias. Third, the included studies exhibit heterogeneity in patient populations, interventions, and follow-up durations, limiting the comparability of results across studies. Fourth, the preferential inclusion of English-language literature may introduce language bias. Finally, in this rapidly evolving field, the current evidence summarized here is subject to change as new findings emerge. Conclusions In recent years, the surgical management of VHD has been shifting away from a decision-making model centered on surgical risk scores towards a more nuanced, individualized approach. A series of studies in 2025 have provided further updates to this paradigm of precision valve care. In the aortic valve arena, while long-term follow-up data in low-risk patients show no significant difference between TAVR and SAVR, real-world practice and subgroup analyses suggest that valve morphology, patient sex, and the extent of CAD have an important impact on long-term prognosis. Mitral valve surgery continues to face a gap between real-world practice and RCT results, with the MITRACURE study revealing that issues such as delayed referral and suboptimal repair rates remain areas for improvement. Tricuspid valve interventions are evolving rapidly, and optimal timing of intervention may be key to improving long-term patient outcomes. Emerging technologies have demonstrated preliminary potential, but their long-term effectiveness and clinical value require further validation. In summary, the field is transitioning from “technological accessibility” to “decision optimization”. Future research should continue to refine treatment algorithms for specific patient subsets—including those defined by valve morphology, age, and operative risk—as well as optimize management strategies following transcatheter intervention failure. Long-term surveillance of emerging technologies will be essential to define their role in clinical practice, while efforts to integrate quantitative imaging and decision-support tools may further advance the delivery of individualized valve care. Beyond these areas, the evolving landscape of VHD will undoubtedly present additional questions that warrant ongoing investigation. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0842/prf